Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
Xiaoqi Yu, Dong Wei, Wenxin Xu, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 80

Showing 26-50 of 80 citing articles:

Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine
Shanhe Yu, Yingni Lin, Yong Li, et al.
Cell (2023) Vol. 186, Iss. 21, pp. 4615-4631.e16
Open Access | Times Cited: 15
Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines
Jie Zhou, Zezhong Liu, Guangxu Zhang, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 22
Key Essentials during the Transition from the Acute Phase of the COVID-19 Pandemic
Piotr Rzymski, Maria Pokorska‐Śpiewak, Teresa Jackowska, et al.
(2023)
Open Access | Times Cited: 11
Dynamic Profiling and Prediction of Antibody Response to SARS-CoV-2 Booster-Inactivated Vaccines by Microsample-Driven Biosensor and Machine Learning
Sumin Bian, Min Shang, Ying Tao, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 352-352
Open Access | Times Cited: 4
Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough
Yichuan Yao, Yunru Yang, Qiqin Wu, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
Rapid clonal expansion and somatic hypermutation contribute to the fate of SARS-CoV-2 broadly neutralizing antibodies
Miao Wang, Congcong Liu, Qing Fan, et al.
The Journal of Immunology (2025)
Closed Access
Cross-variant immune shield: computational multiepitope vaccine design against B.617.2 to Omicron sub-lineages in SARS-CoV-2
Jinal M. Thakor, Unnati V. Panchal, Dhaval Patel, et al.
Journal of Biomolecular Structure and Dynamics (2025), pp. 1-20
Closed Access
Modeling the effects of cross immunity and control measures on competitive dynamics of SARS-CoV-2 variants in the USA, UK, and Brazil
Komal Basaiti, Anil K. Vashishth, Tonghua Zhang
Mathematical Biosciences (2025), pp. 109450-109450
Closed Access
Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
Daniel Y. Zhu, Matthew J. Gorman, Dansu Yuan, et al.
PLoS Biology (2022) Vol. 20, Iss. 5, pp. e3001609-e3001609
Open Access | Times Cited: 16
Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant
Ioannis Sitaras, Henning Jacobsen, Melissa M. Higdon, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 16
Clinical Characteristics of Omicron SARS-CoV-2 Variant Infection After Non-mRNA-Based Vaccination in China
Qing‐Lei Zeng, Yuanjun Lv, Xiaojing Liu, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 15
Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population
Jiwei Li, Jing Wu, Qiuyue Long, et al.
Research (2022) Vol. 2022
Open Access | Times Cited: 14
Current clinical status of new COVID-19 vaccines and immunotherapy
Diksha Nagpal, Shakti Nagpal, Deepak Kaushik, et al.
Environmental Science and Pollution Research (2022)
Open Access | Times Cited: 14
COVID-19 Vaccines—All You Want to Know
Akira Shishido, Ashley H. Barnes, Shivakumar Narayanan, et al.
Seminars in Respiratory and Critical Care Medicine (2023) Vol. 44, Iss. 01, pp. 143-172
Closed Access | Times Cited: 7
Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population
Sina Hosseinian, Rafael de Assis, Ghali Khalil, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Development trends of human organoid‐based COVID‐19 research based on bibliometric analysis
Minghui Li, Yuhong Yuan, Ting Zou, et al.
Cell Proliferation (2023) Vol. 56, Iss. 12
Open Access | Times Cited: 7
An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
Anna Offersgaard, Carlos Rene Duarte Hernandez, Shan Feng, et al.
iScience (2023) Vol. 26, Iss. 2, pp. 105949-105949
Open Access | Times Cited: 6
Antibody response to the third dose of inactivated COVID‐19 vaccine in people living with HIV (PLWH): A longitudinal cohort
Guang Zeng, Fei He, Xiaomin Zhang, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 5
Closed Access | Times Cited: 6
Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
Xiaolan Yong, Jun Liu, Ying Zeng, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 3
Open Access | Times Cited: 6
Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics
Alexander Kudryavtsev, Anna Vakhrusheva, Valery Novoseletsky, et al.
(2022)
Open Access | Times Cited: 10
Old Age is an Independent Risk Factor for Pneumonia Development in Patients with SARS-CoV-2 Omicron Variant Infection and a History of Inactivated Vaccine Injection
Xuecheng Tong, Zeyu Huang, Xiujun Zhang, et al.
Infection and Drug Resistance (2022) Vol. Volume 15, pp. 5567-5573
Open Access | Times Cited: 10
Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity
Min Joo Choi, Jung Yeon Heo, Yu Bin Seo, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 5
Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection
Entao Li, Qiuxue Han, Jinhao Bi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Azvudine and mortality in patients with coronavirus disease 2019: A retrospective cohort study
Bin Liu, Mingjin Yang, Li Xu, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110824-110824
Closed Access | Times Cited: 5
More effective vaccines and oral antivirals: Keys for the battle against Omicron
Hongzhou Lu
BioScience Trends (2022) Vol. 16, Iss. 1, pp. 1-3
Open Access | Times Cited: 8

Scroll to top